Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy of Hydroxychloroquine in Pre-Exposure Severe Acute Respiratory Syndrome Coronavirus 2 Prophylaxis Among High-Risk Healthcare Workers: A Multicenter Study Publisher



Nasri E1 ; Fakhim H1, 2 ; Salahi M1 ; Ghafel S1 ; Pourajam S3 ; Darakhshandeh A3 ; Kassaian N1 ; Sadeghi S3 ; Ataei B2 ; Javanmard SH4 ; Vaezi A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran
  5. 5. Department of Medical Laboratory Science, School of Allied Medical Sciences, Iran University of Medical Sciences, Isfahan, Iran

Source: Advanced Biomedical Research Published:2023


Abstract

Background: Prophylaxis could be an established strategy to potentially prevent and control infectious diseases and should be considered in the coronavirus disease 2019 (COVID-19) pandemic. The present study aimed to assess the effectiveness of hydroxychloroquine as a prophylaxis treatment strategy in the reduction of the risk of COVID-19 among health professionals. Materials and Methods: The health professionals were randomly assigned (1:1) to the control group without receiving any hydroxychloroquine as prophylaxis and the hydroxychloroquine group receiving a weekly hydroxychloroquine dose of 400 mg up to 12 weeks. Results: A total of 146 health professionals were randomly enrolled in this study between August 11 and November 11 in 2020. Among the screened health professionals, 21 (14.6%) were infected with COVID-19 during the 12 weeks, and 14 (66.6%) out of the 21 health professionals were in the control group. Most participants with COVID-19 had mild symptoms (62%). In addition, 9.5% (n = 2) of the participants suffered from moderate disease and 28.5% were diagnosed with severe symptoms. In the hydroxychloroquine group, 5 (7.1%) and 2 (2.8%) participants were reported with mild and moderate symptoms of COVID-19, respectively, and 2 participants had moderate, 8 (10.9%) participants had mild symptoms, and 6 (8.2%) participants had severe symptoms in the control group, within 3 months. Severe symptoms of COVID-19 were not observed in the hydroxychloroquine group. Conclusion: This study addressed the effect and benefit of hydroxychloroquine administration for the prevention of COVID-19 among health professionals. The improved perception of prophylaxis might highlight its important role in future COVID-19 outbreaks to prevent hospital transmission, which is a major route of spread. © 2023 The Author(s).
Other Related Docs
11. Covid-19 Management in the Emergency Ward, Journal of Research in Medical Sciences (2021)
12. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)
14. A Narrative Review of Covid-19: The New Pandemic Disease, Iranian Journal of Medical Sciences (2020)
19. Ramadan Fasting and Risk of Covid-19, International Journal of Preventive Medicine (2020)
23. Epidemiological Study of Covid-19 in Iran and the World: A Review Study, Infectious Disorders - Drug Targets (2022)
26. Covid19 Prevention & Care; a Cancer Specific Guideline, Archives of Iranian Medicine (2020)
36. Important Guidelines for Surgery in Covid-19 Pandemic; a Review Study, Journal of Isfahan Medical School (2021)
40. Epidemiological Features of Covid-19 in Iran, Journal of Research in Medical Sciences (2022)
41. Clinical Display, Diagnostics and Genetic Implication of Novel Coronavirus (Covid-19) Epidemic, European Review for Medical and Pharmacological Sciences (2020)
43. Prediabetes and Covid-19 Severity, an Underestimated Risk Factor: A Systematic Review and Meta-Analysis, Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2021)
46. Potential Inhibitors of Sars-Cov-2: Recent Advances, Journal of Drug Targeting (2021)